phosphorylation is ubiquitously used to control the activity of numerous intracellular enzymes, which allows rapidly switching proteins from an inactive state to an active state and vice versa. In B-CLL, cell proliferation strongly depends on the function of the ribosomal s6 kinase (p70S6K).
3 p70S6K is a highly conserved protein kinase downstream of the mammalian target of rapamycin (mTOR) and regulates the translation of mRNAs encoding proteins of the translational apparatus. The activation of p70S6 kinase requires phosphorylation of several threonine and serine sites. mTOR activates p70S6 kinase through phosphorylation on threonine 389. We observed that threonine phosphorylation of p70S6 kinase was readily detected 3 h after treatment with DSP30 and IL-2, whereas co-treatment of cells with Teriflumomide significantly diminished the phosphorylation of p70S6 kinase (data not shown). Because Leflunomide is known to inhibit tyrosine phosphorylation but not serine or threonine phosphorylation, the inhibitory effect on threonine-389 phosphorylation is unlikely to be a direct effect of Leflunomide. We hypothesized that Leflunomide acts upstream of mTOR in activated B-CLL cells by interrupting signal-transduction pathways leading to mTOR activation.
In addition to its growth inhibitory effect on activated CLL cells, Teriflunomide induces apoptosis in peripheral B-CLL cells arrested in G1 (Figure 3 ). This effect is restricted to ZAP70-positive cells. Although currently we do not understand the differences of apoptosis induction between ZAP70-positive and -negative cells, we believe that the proapoptotic response of B-CLL cells to Teriflunomide is of clinical importance for this subgroup of patients with a poor prognosis. An increasing body of evidence has demonstrated that the apoptotic defect of B-CLL cells depends on the constitutive activation of several signaling pathways; among these, PI3-kinase/PKC-d and nuclear factor-kappa B are important. 4 In light of these aberrant signaling pathways, it is tempting to speculate that Leflunomide interferes with constitutively activated signaling pathways through its capacity to inhibit tyrosine phosphorylation, thereby inducing apoptosis in this subset of B-CLL cells. We assume that pro-mitotic factors, such as DSP30/IL-2, provide antiapoptotic signals, which prevent Leflunomide from inducing apoptosis in activated, ZAP70-positive B-CLL cells.
In conclusion, we identified that the immunomodulatory drug Leflunomide not only inhibits cell cycle progression of activated CLL cells but also induces apoptosis in ZAP70-positive, G1-arrested cells. These properties of Leflunomide might be an advantage over rapamycin, another cell cycle inhibitor, which lacks proapoptotic effects on quiescent B-CLL cells. 3 Extensive experience from clinical trials with Leflunomide in patients with rheumatoid arthritis has demonstrated that it is well tolerated, with only mild to moderate side effects. In light of its antileukemic effects on different cellular compartments, particularly in CLL patients with an unfavorable prognosis, Leflunomide is a promising new candidate for the treatment of CLL patients. Accumulating evidence indicates that hypermethylation of CpG islands (CGIs) is a prevalent molecular event in human cancers, and the list of genes affected continues to grow. When a normally unmethylated CGI located within the promoter or other regulatory region of a gene becomes methylated in cancer cells, the outcome is frequently a loss of expression of adjacent genes. As a step toward a better understanding of this widespread phenomenon, our laboratory utilized a microarray containing 47K CpG loci for DNA methylation analysis to survey the genome-wide methylation present in a subgroup of non-Hodgkin's lymphomas, the small B-cell lymphomas (SBCLs) 1 and acute lymphoblastic leukemia (ALL). 2 These studies identified several genes and loci in which differential methylation was present among histological classes, thus showing that aberrant methylation is a nonrandom event in these malignancies. Several models have been proposed to explain the presence of the nonrandom patterns of methylation in cancer. The first postulates that a genetic event responsible for the activation of an oncogene could trigger the initiation of tumor development through dysregulation of the DNA methylation machinery. A second postulated model suggests that some DNA sequences are readily methylatable while others are not. For example, sequences could be protected from methylation by the presence of DNA binding proteins such as transcription factors, which prevent the methylation machinery from gaining physical access to DNA. Conversely, sequences that are readily methylated may contain specific DNA binding sequence motifs that aid in the Chromosomal localization of aberrantly methylated loci in small B-cell lymphoma (SBCL). Horizontal green lines represent the locations of the CpG clones present on the microarray platform utilized by Rahmatpanah et al. 1 and Taylor et al. 2 Each aberrantly methylated locus is represented by a black horizontal line in chronic lymphocytic leukemia (CLL) (red chromosome), follicular lymphoma (FL) (blue chromosome) and mantle cell lymphoma (MCL) (violet chromosome). Each locus that is associated with a known gene is labeled to the right of the chromosome. Genes that are methylated in FL and MCL are indicated by light blue boxes, those that are methylated in CLL, FL and MCL are indicated by orange boxes and those that are methylated in CLL and MCL are indicated by pale yellow boxes. recruitment of DNA methyltransferases (DNMTs). The third model is based on nuclear architecture and postulates that certain regions of the nucleus are more or less prone to aberrant methylation based on the level of chromatin compaction at any point in time. Each of these proposed models allows for establishment of nonrandom patterns of DNA methylation, but it is likely that some combinations of these proposed mechanisms are responsible for the patterns of aberrant methylation observed in cancer.
To begin to decipher the possible contribution(s) of chromosomal territories to the nonrandom patterns of aberrant methylation observed in SBCL, each methylated locus identified by Rahmatpanah et al.
1 was mapped to its genomic location in chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and mantle cell lymphoma (MCL) using MapChart & software 3 ( Figure 1 ). Using the same criteria as in our earlier work (X1.5-fold difference between tumor and normal tissue and present in at least 25% of patients), 3 aberrantly methylated loci were observed in CLL, 98 in FL and 59 in MCL. Most studies investigating aberrant methylation in cancer to date have focused on CGIs present within the promoters of genes because it is believed that methylation within these CpG dense regions is most likely to have an effect on transcription of the associated gene. If only those loci associated within the promoter of a gene are considered, 3 aberrantly methylated loci were observed in CLL, 60 in FL and 39 in MCL. However, there is also evidence that methylation present further downstream from the promoter and exon 1 is also capable of regulating gene expression. Therefore, we believe that the overall pattern of methylation, regardless of whether the loci are present within the promoters of genes, may facilitate a better understanding of the mechanism(s) underlying gene dysregulation observed in cancers. We used a robust nonparametric statistical test for chromosomewide methylation localization and clustering that takes all loci into consideration (see Taylor et al. 2 for more details). Statistically significant clustering of aberrantly methylated loci was detected on chromosomes 2 (P ¼ 0.0005), 9 (P ¼ 0.0374) and 19 (P ¼ 0.0078) in FL but was not detected in CLL or MCL. This suggests the possibility that chromosome region-specific targeting may contribute to the nonrandom patterns of methylation observed in FL. Such a process has been recently reported in other tumor types, and has shown that instructive mechanisms likely contribute to directed methylation on chromosomes and that genes from entire regions of chromosomes can be affected epigenetically.
We previously identified 262 aberrantly methylated loci in ALL patients and found clusters of methylated loci also including a region on chromosome 19. 2 Since both ALL and FL have clusters of methylated loci on chromosome 19, we compared the genomic locations of the aberrantly methylated loci in these two distinct lymphoid malignancies (Figure 2 ). Chromosome 19, in addition to comprising the highest gene density of all human chromosomes, also harbors several kallikrein genes (implicated in carcinogenesis), leukocyte immunoglobulin-like receptors and zinc-finger proteins. The observed clusters of methylated loci in both ALL and FL encompass 19q13.2-q13.4, which is believed to harbor tumor suppressor genes associated with many types of cancer (that is, ovarian, brain, colorectal, skin, breast and lung). Also included in this region are the DNA repair genes ERCC1, ERCC2 and LIG1, which are excellent candidate tumor suppressor genes since it is well known that genes involved in DNA repair and the maintenance of genome integrity are critically involved in protecting against cancer.
Silencing of certain DNA repair genes by DNA methylation might be related to the occurrence of tumorigenic mutations 4 and play a critical role in the development of cancer; these genes functioning normally would prevent the accumulation of mutations leading to carcinogenesis. Both ALL and FL are derived from lymphoid cells, which in the normal state are undergoing rapid rearrangements of immunoglobulin genes either in the bone marrow (ALL) or in the peripheral lymphoid tissues (FL). Although even single-strand breaks in DNA that are unfaithfully repaired are important, the double-stranded break (DSB) is probably the most dangerous of the many types of DNA damage that exist within the cell. DSBs can arise after exposure to ionizing radiation, chemotherapeutic drugs or from chromosomal stress but also occur during normal lymphoid development. For example, during V(D)J recombination and immunoglobulin class-switch recombination, DSBs occur as intermediates. Inaccurate repair or lack of repair of DSBs can have detrimental consequences as a result of mutations or genomic instability, which could lead to the development of cancer. In fact, both ALL and FL have characteristic oncogenic chromosomal rearrangements that have arisen as a consequence of defective DSB repair. Characteristic gains and losses of chromosomal material through incomplete DNA repair are associated with the activation of proto-oncogenes and also inactivation of tumor suppressors. In addition, since DNMTs are associated with DNA repair 5 and it is known that DNA methyltransferase I expression is significantly higher in normal germinal-center B cells (whose malignant counterpart is FL) than in normal naïve, memory, mantle zone or marginal zone B cells, 6 it is possible that an increase in DNMT expression during DNA repair plays a mechanistic role in the overabundance of methylated genes.
This leads to the most important question to be answered in future studies 'What is the underlying cause of the nonrandom and seemingly targeted methylation observed in FL?' One possible explanation is that a subset of the aberrantly methylated loci harbors a common DNA binding motif, which is responsible for the binding of factors that promote aberrant methylation. A second plausible explanation is that an initiation event, such as uracil misincorporation or induced abasic sites, occurs in a particular genomic region followed by the spreading of methylation across sites in close proximity to the original initiation event. Based on our identification of methylation hot spots associated with ALL on chromosomes 19, 18 and 11, and with FL on chromosomes 19, 9 and 2, we believe that nuclear organization involving chromosome 19 may also play a role in aberrant methylation. Furthermore, the presence of clusters of aberrantly methylated loci in a region of chromosome 19 that is believed to harbor tumor suppressor genes and is known to harbor genes involved in DNA repair, together with the fact that the cells from which both ALL and FL are derived are subjected to DSBs, suggests that this region of chromosome 19 may harbor putative tumor suppressor genes associated with ALL and FL. Unfortunately, due to the limited genomic resolution of the microarray platform that was utilized and the dependence of our analysis on restriction enzyme recognition sequences, we view our findings to this point as preliminary discoveries that should lead to a full re-examination of the 'complete' methylome in ALL and NHL using more comprehensive assay technologies. If confirmed in a larger study, the potential impact of this finding is significant since it is possible that methylation is capable of spreading across chromosomal regions in close proximity and, as shown by others, epigenetic modifications such as this can lead to silencing of multiple genes in a coordinate fashion. These results are particularly interesting because chromosomes colocalize temporally in resting and activated B cells 7 and, in some instances, nuclear architecture is thought to affect a number of processes including epigenetic mechanisms. 8 This argument suggests that the physical proximity of specific chromosomal regions within the nucleus at key points during the cell cycle (or neoplastic transformation) might facilitate the initiation and spreading of methylation and gene silencing.
Non-specific amplification of patient-specific Ig/TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring Several studies have shown that detection of minimal residual disease (MRD) has prognostic relevance in childhood and adult acute lymphoblastic leukemia (ALL), both at initial diagnosis, at relapse, and before stem cell transplantation. Consequently, MRDbased therapy stratification nowadays is being included in many ALL treatment protocols. In most clinical ALL studies, MRD is being evaluated by real-time quantitative PCR (RQ-PCR) analysis of immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements, which serve as patient-specific markers for the leukemic cells.
Recently, the European Study Group on MRD detection in ALL developed guidelines for the interpretation of RQ-PCR data, 1 which are crucial for multi-center MRD studies. 2 These guidelines include a definition of the 'Quantitative Range' (the reproducible part of the assay in which data can accurately and reliably be quantified) and definitions of MRD positivity. In these definitions, the presence and level of non-specific amplification (NSA) plays an important role. NSA is dependent on the Ig/TCR locus involved, the gene segments used and the number and type of deleted and inserted nucleotides in the junctional region. For example, NSA occurs in about 35% of IGH targets (particularly those using the JH4, JH5 or JH6 gene segment) and in over 90% of TCRG targets. 3 Most laboratories determine the NSA by analysis of DNA obtained from peripheral blood (PB) buffy coats from a pool of five to ten healthy blood donors. However, most MRD-based stratifications in ALL are based on MRD levels in bone marrow, and NSA in bone marrow may well be different from NSA observed in PB buffy coat DNA obtained from healthy donors. For example, based on the previously reported variation in the cellular composition of the bone marrow during and after therapy, 4-6 the ESG-MRD-ALL assumed that the level of NSA in bone marrow is not constant but varies, dependent on the time point at which the sample was taken. In order to allow such variations in NSA without affecting the reliability of the RQ-PCR assay, the ESG-MRD-ALL decided that the NSA should have a certain 'distance' from the Quantitative Range. In fact, the cycle threshold (C T ) of the lowest dilution of the Quantitative Range
